Esperion Therapeutics, Inc.
Here’s whether Esperion Therapeutics, Inc. (ESPR) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bearish.
Positives: strong 1-year return of +111.6%. Concerns: trading below the 200-day MA (long-term downtrend); below the 50-day MA (medium-term momentum negative); 50-day MA is falling (-7.71% over 10 days); RSI 23 — oversold; 3-month momentum negative (-32.9%); rising volume on a downtrend (distribution, 1.30x avg). Currently 51.1% off its 52-week high. Score: -5/7.
ESPR is trading below its 200-day MA ($2.75) — a key warning sign the longer-term trend is under pressure. An RSI of 23.1 has dropped into oversold territory, which has historically preceded short-term bounces. The 1-year return of +111.6% compares to +35.1% for SPY (beat the market by 76.5%). The current 51.1% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.